Drug Trial Radar · NCT07711002
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,330
Planned (sponsor's estimate)
Start
Sep 15, 2026
Primary completion
May 30, 2031
Study completion May 27, 2033
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received docetaxel chemotherapy or a prostate-specific membrane antigen (PSMA)-directed lutetium-177 radioligand therapy with no evidence of disease progression and PSA ≥ 0.2 ng/mL.
Conditions
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
SaruparibDrug
Arm 1: Saruparib (AZD5305) + Physician's Choice ARPI (enzalutamide, darolutamide, or abiraterone)
PlaceboOther
Arm 2: Placebo + Physician's Choice ARPI (enzalutamide, darolutamide, or abiraterone)
EnzalutamideDrug
Arm 1: Saruparib (AZD5305) + Physician's Choice ARPI (enzalutamide, darolutamide, or abiraterone) Arm 2: Placebo + Physician's Choice ARPI
DarolutamideDrug
Arm 1: Saruparib (AZD5305) + Physician's Choice ARPI (enzalutamide, darolutamide, or abiraterone) Arm 2: Placebo + Physician's Choice ARPI
AbirateroneDrug
Arm 1: Saruparib (AZD5305) + Physician's Choice ARPI (enzalutamide, darolutamide, or abiraterone) Arm 2: Placebo + Physician's Choice ARPI
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiographic progression-free survival (rPFS)Time frame: Up to approximately 56 months
Locations
210 sites in 21 countries. Site status is shown where the registry gives one.
Research Site
Hot Springs, Arkansas · Not yet recruiting
Research Site
Springdale, Arkansas · Recruiting
Research Site
Beverly Hills, California · Not yet recruiting
Research Site
Los Alamitos, California · Not yet recruiting
Research Site
Los Angeles, California · Not yet recruiting
Research Site
San Diego, California · Withdrawn
Research Site
Margate, Florida · Recruiting
Research Site
Miami, Florida · Recruiting
Research Site
Orlando, Florida · Not yet recruiting
Research Site
Honolulu, Hawaii · Not yet recruiting
Research Site
Chicago, Illinois · Not yet recruiting
Research Site
Chicago, Illinois · Not yet recruiting
Research Site
Elk Grove Village, Illinois · Not yet recruiting
Research Site
Hinsdale, Illinois · Not yet recruiting
Research Site
Ames, Iowa · Not yet recruiting
Research Site
Baltimore, Maryland · Not yet recruiting
Research Site
Baltimore, Maryland · Not yet recruiting
Research Site
Towson, Maryland · Not yet recruiting
Research Site
Detroit, Michigan · Not yet recruiting
Research Site
Grand Rapids, Michigan · Not yet recruiting
Research Site
Marshall, Minnesota · Not yet recruiting
Research Site
Camden, New Jersey · Not yet recruiting
Research Site
Albuquerque, New Mexico · Not yet recruiting
Research Site
Shirley, New York · Not yet recruiting
Research Site
Canton, Ohio · Not yet recruiting
Research Site
Cincinnati, Ohio · Not yet recruiting
Research Site
Portland, Oregon · Not yet recruiting
Research Site
Portland, Oregon · Not yet recruiting
Research Site
Greenville, South Carolina · Not yet recruiting
Research Site
Aberdeen, South Dakota · Not yet recruiting
Research Site
Mitchell, South Dakota · Not yet recruiting
Research Site
Pierre, South Dakota · Not yet recruiting
Research Site
Sioux Falls, South Dakota · Not yet recruiting
Research Site
Yankton, South Dakota · Not yet recruiting
Research Site
Nashville, Tennessee · Not yet recruiting
Research Site
Austin, Texas · Not yet recruiting
Research Site
Dallas, Texas · Not yet recruiting
Research Site
Fort Worth, Texas · Not yet recruiting
Research Site
Longview, Texas · Not yet recruiting
Research Site
Wichita Falls, Texas · Not yet recruiting
Showing 40 of 210 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.